Regenerative Therapies for Neurological Disorders
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SanBio is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, diseases of the eye, and Parkinson's disease.
SanBio is a scientific leader in cell therapies for regenerative medicine. Clinical testing for SanBio's products is underway.
Gary Steinberg, MD, PhD, Professor, Chair, Stanford University School of Medicine – Neurosurgery (Principal Investigator for SanBio SB623 stroke clinical trial)
Pittsburgh (CBS2 KDKA): Researchers Testing Stem Cells as Treatment for Stroke Recovery
April 17, 2015
SanBio Announces Updated Pricing for Initial Public Offering on Tokyo Stock Exchange.
April 8, 2015
SanBio Announces Pricing for Initial Public Offering on Tokyo Stock Exchange.
September 29, 2014
SanBio Announces Joint Development and License Agreement with Sumitomo Dainippon Pharma.
August 4, 2014
SanBio Announces Appointment of Chief Medical Officer.
February 14, 2014
SanBio Announces the First Public Presentation of Data from Its On-Going Human Clinical Trial of Cell Therapy for Chronic Stroke Disability.
September 4, 2013
SanBio Announces the Completion of Enrollment of Its Clinical Trial of Cell Therapy for Chronic Stroke Deficits.
231 S. Whisman Road
Mountain View, CA 94041-1522
info at san-bio dot com
Site Design: Formative